Biopharmaceutical company Akeso Inc (HK:9926) announced on Monday that it is presenting the late-breaking abstract from the registrational Phase III clinical study (AK112-306/HARMONi-6 study) of ivonescimab, a globally first-in-class bispecific antibody targeting PD-1 and VEGF, at the 2025 European Society for Medical Oncology (ESMO) Annual Congress.

The study evaluates ivonescimab in combination with chemotherapy compared to tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). It has been selected for the Presidential Symposium.

Results of the study will be presented by the principal investigator, Professor Lu Shun, Director of the Department of Oncology at Shanghai Chest Hospital.

According to Akeso, the findings provide a comprehensive overview of the efficacy and favourable safety profile of ivonescimab in combination with chemotherapy for the treatment of first line advanced squamous NSCLC.